Tepoditamab

Tepoditamab (MCLA-117) is a full-length human IgG1 bispecific monoclonal antibody that binds to CLEC12A of myeloid cells and CD3 of cytotoxic T cells. Among others, CLEC12A is a myeloid differentiation antigen. Tepoditamab kills AML leukaemia mother cells and AML leukaemia stem cells, induces T cell-mediated proliferative lysis of AML cells. Tepoditamab induces upto 30-fold T-cell expansion. Tepoditamab results in moderate to strong cytokine (IFNγ, IL-6, IL-8, IL-10, and TNFα) and IFNγ release in human whole blood and PBMC, respectively. Tepoditamab can be used in acute myeloid leukaemia (AML) research[1][2][3].

Product Specifications

CAS Number

[2044679-53-8]

Product Name Alternative

MCLA 117

UNSPSC

12352203

Target

CD3; IFNAR; Interleukin Related; TNF Receptor

Type

Inhibitory Antibodies

Related Pathways

Apoptosis; Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/tepoditamab.html

Purity

Solubility

10 mM in DMSO

Smiles

[Tepoditamab]

Molecular Weight

(144.787 kDa)

References & Citations

[1]Naval Daver, et al. T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments. Leukemia. 2021 Jul;35 (7) :1843-1863.|[2]van Loo, P. F., et al., (2019) . MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis. Expert opinion on biological therapy, 19 (7), 721–733. |[3]Pieter Fokko Van Loo, et al., Preclinical Evaluation of MCLA117, a CLEC12AxCD3 Bispecific Antibody Efficiently Targeting a Novel Leukemic Stem Cell Associated Antigen in AML, Blood, Volume 126, Issue 23, 2015.